Moderna announces first participant dosed in phase 2 study of omicron-specific booster candidate and publication of data on booster durability against omicron variant

Phase 2 study of omicron-specific booster candidate ( mrna-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mrna-1273 and another including participants who received the two-dose primary series and a 50 Μg booster dose of mrna-1273 omicron neutralization six months after the third 50 Μg dose of mrna-1273 declined, but remained detectable in all participants cambridge, ma / accesswire / january 26, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the first participant has been dosed in the phase 2 study of the company's omicron-specific booster candidate (mrna-1273.529). additionally, moderna announced the publication of neutralizing antibody data against the omicron variant six months following a booster dose in the new england journal of medicine.
MRNA Ratings Summary
MRNA Quant Ranking